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The prevalence of congenital anomalies in newborns is estimated to be as high
as 6%, many of which involving the cranio-/orofacial region. Such malformations,
including several syndromes, are usually identified prenatally, at birth, or rarely later
in life. The lack of clinically relevant human cell models of these often very rare
conditions, the societal pressure to avoid the use of animal models and the fact that
the biological mechanisms between rodents and human are not necessarily identical,
makes studying cranio-/orofacial anomalies challenging. To overcome these limitations,
we are developing a living cell repository of healthy and diseased cells derived from the
cranio-/orofacial region. Ultimately, we aim to make patient-derived cells, which retain
the molecular and genetic characteristics of the original anomaly or disease in vitro,
available for the scientific community. We report our efforts in establishing a human
living cell bank derived from the cranio-/orofacial region of otherwise discarded tissue
samples, detail our strategy, processes and quality checks. Such specific cell models
have a great potential for discovery and translational research and might lead to a
better understanding and management of craniofacial anomalies for the benefit of all
affected individuals.
Keywords: patient-derived cells, craniofacial anomalies, cell bank, quality control, rare diseases, personalized
medicine
INTRODUCTION
Craniofacial development is a complex process that requires orchestrated interactions of multiple
cell types derived from all germ layers (Kindberg and Bush, 2019). Among them, the neural crest
cells (NCCs) are the most critical population. NCCs arise at the neural plate border, undergo an
epithelial-mesenchymal transition (EMT), and then are guided to the periphery where they form
the structures of the head and the face (Hall, 2000; Cordero et al., 2011; Green et al., 2015; Siismets
and Hatch, 2020). All these intricate steps rely on precise spatio-temporally regulated networks
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 June 2021 | Volume 9 | Article 682944
fcell-09-682944 June 4, 2021 Time: 17:57 # 2
Parisi et al. CFA Cell Bank
of signaling cues, which, due to their complexity, are error prone,
and may result in a diversity of craniofacial anomalies (CFAs)
(Gorlin et al., 1990). In fact, it is estimated that CFAs occur in
approximately 0.2% of all newborns (Shaw, 2004). Some, like
cleft lip/palate (CLP), are among the most common congenital
abnormalities affecting around 1 in 750 newborns (Kousa and
Schutte, 2016), while others, such as Goldenhar syndrome (GH)
are rarer with an estimated prevalence of 1 in 3000–5000 births
(Bogusiak et al., 2017). CFAs can appear in isolation, as part
of a syndrome with defects due to mutations in single genes
or chromosomal abnormalities, or in combination with other
defects without an identified genetic background.
CFA-affected children usually require surgery in order
to repair the most debilitating defects, which is routinely
followed by personalized treatment throughout childhood and
adolescence. Although the surgical procedures have been
optimized during the last decades, a number of common
complications in CFA-affected children may still persist even
after surgery, such as difficulties in feeding, speech and hearing,
impaired dentition and wound healing complications (van
Beurden et al., 2005; Aizenbud et al., 2011; Hortis-Dzierzbicka
et al., 2012). These problems might require additional surgeries,
which can be challenging as often not enough tissue is available
to correct the anomaly (i.e., alveolar bone defects in CLP
patients) (Zhang and Yelick, 2018). In addition, CFAs are
still associated with an increased mortality as well as with a
negative impact on a child’s self-perception and social integration
due to esthetical concerns. Consequently, CFAs represent a
high economic, social, and psychological burden for affected
individuals, their families, and the society as a whole. Therefore,
there is an urgent need for a better understanding of CFAs, which
could allow to optimize treatment options tailoring it to the
specific patient needs.
Discovery molecular and cellular research on human CFAs is
challenging due to the lack of proper models. At the moment
knowledge is mostly based on animal studies. Fortunately,
craniofacial development is a highly conserved process across
many species (Hu et al., 2003) and mice and humans share the
majority of protein-coding genes (Yue et al., 2014). However,
certain discrepancies exist between humans and animals in
regard to facial morphogenesis. For instance, disruption of
genes in mice, which have been linked to CLP in humans,
often do not perturb the formation of the primary palate
and the lip in the animal and hence, produce only a
cleft palate (CP) phenotype (Gritli-Linde, 2008; Van Otterloo
et al., 2016). As not every finding in animal models can be
transferred to humans, and considering the strong urge from
the society to minimize animal experimentation by using other
studies modalities, CFA patient-derived cells might represent
an alternative in vitro study tool. However, working with
primary cells is often experienced as cumbersome, since they
require an established isolation protocol, unique growth media,
more care in general, and they exhibit a limited lifespan.
The use of postnatal tissues to study CFAs that arise early
in development also comes with challenges and assumptions
regarding the retention of the original tissue characteristics.
However, increasing evidence shows the persistence of various
cellular properties postnatally in tissues as well as in patient-
derived cells (Beyeler et al., 2014; Hixon et al., 2017; Degen et al.,
2018, 2020). In this regard, it is also noteworthy to mention
that often it is very ambitious and difficult to have access to
proper healthy control tissue and/or cells, which ideally should
be age- and anatomically matched to the studied condition
(Degen et al., 2020).
To facilitate the use of patient-derived cells as clinically
relevant cell models to study CFAs, we have initiated a project
to establish a living cell repository of the cranio-/orofacial
region starting from routinely discarded tissue biopsies. To this
purpose, we collaborate with the Pediatric Surgery Division,
Children’s Hospital, Bern, which is responsible for the surgical
treatment of CLP-affected infants. In CLP patients, the cleft
lip is closed at the age of about 4 months, after removing a
small piece of superfluous lip tissue reaching into the cleft. We
collect this excessive CLP lip tissue as well as healthy pediatric
tissue remnants, obtained from the surgical management of
minor injuries (i.e., lip lacerations) often requiring debridement.
Similarly, numerous clinical samples are obtained during routine
dental treatments, which take place on a daily basis at the
Dental School, University of Bern, to which our laboratory
is affiliated. Such samples include small tissue biopsies from
the gingiva, the periodontal ligament (PDL) and the dental
pulp from extracted healthy wisdom teeth, and the hard/soft
palate. All these excised tissues are usually discarded since
most of these conditions do not require any further diagnostic
analyses. Such tissue remnants serve as optimal and easily
accessible sources for the isolation of primary cells and for
the establishment of a high-quality and readily available cell
repository of the cranio-/orofacial region for discovery and
translational research.
The aim of this report is to present our proof-of-
concept study in creating a robust and high-quality cell
bank and in exploiting its full potential for translational
applications. Such a unique effort holds great promises in
fostering scientific collaborations in the field of cranio-/orofacial
development, thereby advancing and promoting personalized
precision medicine for unmet medical needs.
MATERIALS AND METHODS
Cell Isolation and Culture
Tissue biopsies were collected in 50 ml conical tubes containing
≈ 25 ml of Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco/Life Technologies; Thermo Fisher Scientific, Lucerne,
Switzerland) containing 10% fetal calf serum (FCS) (Sigma-
Aldrich, St. Louis, MO, United States), 1× Pen/Strep (PS)
solution (Gibco), and 1× Amphotericin B (AmphB) (Gibco)
[=Collection Medium (CM)]. Samples were transferred to the
research laboratory within 2 h (average time) after biopsy
collection for further processing. In rare case, when urgent
unplanned surgeries/treatments occurred on weekends or during
the night, samples were stored overnight at 4◦C. We did
not notice any negative impact on cell isolation from such
samples. Under sterile conditions, the CM was aspirated, and
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 June 2021 | Volume 9 | Article 682944
fcell-09-682944 June 4, 2021 Time: 17:57 # 3
Parisi et al. CFA Cell Bank
the tissues washed for an additional 5 min in CM. Using
sterile tweezers and scalpels, the specimens were minced
into small pieces (<1 mm3), which were then transferred
into six-well plates containing 800 µl of CM and placed
in a humidified incubator at 37◦C/5% CO2. Two pieces
were incubated per well of a six-well plate. The explant
cultures were carefully washed with CM and re-fed with
fresh medium every other day. Cellular outgrowths were
daily observed under a light microscope and the cell types
growing out of each tissue piece annotated (e.g., fibroblasts
only, keratinocytes only, mixed populations). Cells were allowed
to grow out to colonies of approximately 0.4 cm diameter
before subculturing (passage 1) them into p60 or p100
culture dishes using trypsin/EDTA (TE) solution (Gibco). Pure
fibroblast outgrowths were trypsinized using 0.05% TE and
pure keratinocyte outgrowths using 0.25% TE. For mixed
populations a differential TE approach was used: fibroblasts were
detached first, followed by the dissociation of the keratinocytes.
Keratinocytes were cultured in Keratinocyte serum-free medium
(KSFM) (Gibco/Life Technologies), supplemented with 25 µg/ml
bovine pituitary extract, 0.2 ng/ml epidermal growth factor and
CaCl2 to a final Ca2+ concentration of 0.4 mM and 1× PS
(Gibco), as previously described (Degen et al., 2012). Fibroblasts
were cultured in complete DMEM (Gibco) supplemented with
10% FCS and 1× PS. Cells were expanded in p100 culture
dishes, quality-checked, and frozen at passage 2 (2 × 105–
1 × 106 keratinocytes/vial and 1 × 105–5 × 105 fibroblasts/vial)
in 2× freezing medium (DMEM, 20% FCS, 25 mM HEPES,
20% DMSO) diluted 1:1 in their respective culture medium and
stored in liquid nitrogen. For all experiments cells at passage
3 have been used.
For mycoplasma detection, cells were grown for at least 5 days
in their specific growth media in the absence of any antibiotics.
Afterward cells were fixed in 4% paraformaldehyde (PFA) and
the nuclei stained with DAPI using the Vectashield Mounting
Medium containing DAPI (Vector Laboratories, Burlingame,
CA, United States). In parallel, conditioned medium was
collected from the cells, which was used as template for a PCR-
based mycoplasma detection analysis as described (Praetorius,
2015).
Bone marrow-derived Mesenchymal Stem Cells (MSCs)
(ScienCell, Carlsbad, CA, United States) were cultured in MSC
medium (ScienCell).
RNA Extraction, cDNA Synthesis, and
Quantitative Real-Time PCR (qPCR)
Analysis
Total RNA was isolated using the innuPREP RNA Mini
kit (Analytik Jena AG, Jena, Germany) according to the
standard protocol for eukaryotic cells. RNA concentration was
subsequently measured with a NanoDrop 2000c (Thermo Fisher
Scientific) and stored at−80◦C until use.
A 500 ng of total RNA were used as a template to
synthetize cDNA using the M-MLV Reverse Transcriptase
(Promega, Dübendorf, Switzerland) and Oligo(dT)15 Primer
(Promega). Gene expression was detected by quantitative real-
time polymerase chain reaction (qPCR). qPCR was performed
using a GoTaq R© qPCR Master Mix (Promega) on a QuantStudio 3
instrument (Applied Biosystems, Thermo Fisher Scientific). Data
analysis was performed using the dCT method when absolute
mRNA normalized to GAPDH levels were reported, or by ddCT
method when absolute mRNA normalized to GAPDH were
further referenced to a control sample set to 1.
Sequences of the qPCR primers (Supplementary Table 1)
were either taken from the PrimerBank database1 or from the
NCBI primer designing tool2. All qPCR primer pairs were tested
for specificity and efficiency using cDNA standard curves.
Immunoblotting
Whole cell extracts were prepared in 1× RIPA buffer (10 mM
Tris–HCl pH 8.0, 1 mM EDTA, 0.1% sodium deoxycholate,
0.1% SDS, 1% NP40, 140 mM NaCl) supplemented with
cOmplete MiniTM Protease Inhibitor cocktail and PhosSTOP
EASYpack (both from Sigma-Aldrich). Protein concentrations
were measured using the BCA Protein Assay kit (Pierce, Thermo
Fisher Scientific) following the manufacturer’s recommendation.
10 µg of total protein were diluted in sample loading buffer
(62.6 mM Tris–HCl pH 6.8, 2% SDS, 10% glycerol, 0.01%
bromophenol blue) containing 100 mM dithiothreitol (DTT)
(Sigma-Aldrich), boiled for 5 min at 95◦C and separated
under reducing conditions by SDS-PAGE. Proteins were
subsequently blotted onto nitrocellulose membranes (Sigma-
Aldrich). Membranes were stained with 0.1% amido black
solution (Merck, Burlington, MA, United States) to control
for equal protein loading and blotting efficiency. Afterward,
membranes were washed in Tris-buffered saline (TBS-Tween)
(pH 7.4) containing 0.05% Tween-20, blocked in 3.5% skim
milk powder, incubated over-night with primary antibody at
4◦C, washed three times in TBS-Tween buffer and incubated
with horseradish peroxidase-conjugated anti mouse or rabbit
IgG. Blots were developed using the SuperSignal West Dura
kit (Pierce, Thermo Fisher Scientific). Data were acquired
by scanning membranes with an Imager Chemi Premium
Instrument (VWR, Darmstadt, Germany). Primary antibodies
used are reported in Supplementary Table 2.
Some immunoblots were analyzed densitometrically using
the ImageJ software, version 1.53g (NIH; Bethesda, MA,
United States). Briefly, the intensity of each protein band was
normalized to the β-actin or vinculin band intensity of the same
extract in the same experiment.
Lifespan Analysis
For replicative lifespan analysis, cells were plated at a density of
104/p60 dish for keratinocytes and 105/p100 for fibroblasts in
their standard growth media. Cells were re-fed every other day
and subcultured when reaching 80% of confluency. The day of
subculturing, cells were counted using a Countess 2 automated
cell counter (Thermo Fisher Scientific) and re-seeded at the same
initial cell density. Population doublings (PD) were calculated as
log2 (# cells at the time for subculturing/# cells plated), while
cumulative PDs were plotted against the total days in culture.
1https://pga.mgh.harvard.edu/primerbank/
2www.ncbi.nlm.nih.gov/tools/primer-blast
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Immunofluorescence
For stainings, cells were grown in 35 mm dishes containing
four separate wells (Greiner Bio-One, Frickenhausen, Germany).
Fixation occurred in 4% paraformaldehyde at room temperature
(RT) for 20 min when keratinocytes formed colonies of 8–
10 cells and fibroblasts reached 50% of confluency. Afterward,
cells were rinsed 3 times in Phosphate Buffer Saline (PBS),
permeabilized with 0.1% Triton-X-100 for 5 min, blocked in
3% Bovine Serum Albumin (BSA) (Sigma-Aldrich) for 15 min
and incubated with primary antibody at RT for 2 h. Cultures
were washed three more times in PBS and incubated with
a fluorescent-labeled secondary antibody (Molecular Probes,
Thermo Fisher Scientific) with or without tetramethylrhodamine
(TRITC)-phalloidin (Sigma-Aldrich) for 1 h protected from the
light, washed with PBS and ddH2O, and coverslip mounted
with Vectashield Mounting Medium containing DAPI (Vector
Laboratories). All the samples were examined under an Olympus
BX-51 phase/fluorescence microscope (Olympus Life Science
Solution Tokyo, Japan) equipped with a xenon lamp (X-
Cite, series 120PC Q, Lumen Dynamics, Mississauga, Canada),
and fluorescence filters U-MWIBA3 for Alexa Fluor 488,
U-MWIGA3 for Alexa Fluor 568 and TRITC, and U-MNUA2 for
DAPI (Olympus Life Science Solutions). Images were captured
by a ProgRes CT3 camera with ProgRes Capture Pro software
(Jenoptik, Jena, Germany). Primary antibodies used are reported
in Supplementary Table 2.
Histology
In order to prepare formalin-fixed and paraffin-embedded
(FFPE) blocks, tissue specimens were fixed in 10% formalin,
which is roughly equivalent to 4% formaldehyde, for 48 h
at RT. Samples were then dehydrated with increasing alcohol
concentrations, followed by changes in xylene, before embedding
in paraffin. Five to six-µm sections were finally cut on a Reichert-
Jung microtome (Leica Microsystems, Wetzlar, Germany),
deparaffinized and stained with hematoxylin-eosin (H&E).
Alternatively, after fixation, samples were embedded in acrylic
resin (LR White resin, Sigma-Aldrich), cut into 1 µm sections
with a diamond knife and stained with Toluidine Blue.
All immunohistochemical (IHC) staining reactions were
performed by automated staining using a BOND RX autostainer
(Leica Microsystems). Sections were deparaffinized and antigen
was retrieved using 1mM Tris solution (pH 9.0) for 30 min
at 95◦C. Sections were stained with primary antibodies
(Supplementary Table 2), followed with secondary antibodies,
and specific binding of primary antibodies was visualized using
a polymer-based visualizing system with horseradish peroxidase
as the enzyme and 3,3-diaminobenzidine (DAB) as a brown
chromogen (Leica Microsystems). Finally, the samples were
counterstained with hematoxylin and mounted with Aquatex
(Merck, Burlington, MA, United States). To reveal cartilage,
sections from the GH patient were stained with Safranin-
O. Briefly, sections were deparaffinized and stained with
0.1% Safranin-O solution (Sigma-Aldrich) for 5 min at RT,
followed by rinses with ddH2O and nuclei counterstaining using
hematoxylin. After extensive washes under running tap water,
samples were mounted using resinous medium.
All samples were examined under an Axio Imager M2
microscope (Carl Zeiss, Oberkochen, Germany) and images
taken using a digital AxioCam MRc camera (Carl Zeiss).
3D-Skin Models
To generate 3D-skin models using patient-derived keratinocytes,
the protocol from CELLnTEC (CELLnTEC advanced cells
systems AG, Bern, Switzerland) was used. Briefly, cells were
seeded in 400 µl KSFM into polycarbonate inserts (0.4 µm
pore size, 12 mm diameter, Nunc, Thermo Fisher Scientific)
placed in 60 mm tissue culture dishes, immediately followed by
the addition of 11 ml of KSFM outside the inserts. Confluent
monolayer formation was confirmed with the staining kit (CnT-
ST-100, CELLnTEC). If confluent, keratinocyte differentiation
was induced in parallel cultures by the replacement of KSFM
with 3D Barrier Medium (CnT-PR-3D, CELLnTEC) inside and
outside of the insert (equal medium level) overnight. The
insert was then lifted to the air-liquid interface by carefully
removing the medium inside the insert and replenishing the
outside medium with fresh 3D Barrier Medium up to the
level of the membrane (approximately 3.2 ml for a p60
culture dish). Keratinocytes were cultured for 15 days at 37◦C
and 5% CO2 with medium change every other day. For
full-thickness skin models, fibroblasts were cultured without
any antibiotics and seeded into polyethylene terephthalate
(PET) inserts at 5 × 104 cells per insert and grown for
10 days before adding keratinocytes on top in a fully defined
co-culture medium for culture at the air liquid-interface
(CnT-PR-FTAL, CELLnTEC). Three days after seeding the
keratinocytes on top of the dermal layer, the models were air-
lifted and grown for further 12 days with medium changes
three times per week.
To analyze the skin models, 3D-cultures were fixed overnight
at 4◦C in 4% PFA. Membranes were cut out of the inserts, placed
between two biopsy pads in embedding cassettes, and stored
in 0.1 M sodium cacodylate buffer at 4◦C before proceeding
for paraffin embedding and sectioning on a Reichert-Jung
microtome (Leica Microsystems). Slides containing 5 µm thick
paraffin sections were deparaffinized and rehydrated through
xylene, ethanol, and ddH2O, stained with H&E or primary
antibodies as described in section Histology. Primary antibodies
used are reported in Supplementary Table 2.
MTT-Assay
To evaluate the cytotoxic effects of a commercially available oral
rinse (OR) on gingival fibroblasts and keratinocytes, an MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay was performed (Sigma-Aldrich). Briefly, cells were seeded
in triplicates at a density of 300 cells/mm3 in 96-well plates.
24 h after seeding, they were rinsed twice in PBS and exposed
to different concentrations of the OR for 2 min. Subsequently,
cells were incubated with MTT solution at a final concentration
of 0.5 mg/ml for 4 h to allow MTT conversion into formazan
in metabolically active cells. After two PBS washes, converted
MTT was solubilized with 4N HCl and the absorbance read
at 570 nm on an EL808 BioTek microplate reader (BioTek,
Winooski, VT, United States).
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In vitro Differentiation
For in vitro differentiation, MSCs and PDL fibroblasts at a
density of 105 cells/well of a six-well plate were seeded in their
respective growth medium. 24 h afterward, medium was replaced
with osteogenic medium [αMEM (Thermo Fisher Scientific)
supplemented with 0.05 mg/ml L-Ascorbic acid, 0.01 M β-
Glycerol Phosphate, and 0.1 mM Dexamethasone (all from
Sigma-Aldrich)] for 21 days with medium change every third
day. At the end of the culturing time, cells were fixed in 4% PFA
for 20 min at RT, rinsed with ddH2O and finally incubated with
Alizarin Red S solution [68.45 mg Alizarin Red S (Sigma-Aldrich)
in 5 ml ddH2O, pH 4.1–4.5] for 45 min at 4◦C protected from
light. After extensive washing in ddH2O, samples were air-dried
and analyzed with a light microscope.
Statistical Analysis
Experiments were performed at least three times in multiple
replicates. Data were analyzed using Prism 7 (GraphPad; La Jolla,
CA, United States). Data are represented as means ± standard
deviation (SD). Multiple comparisons were performed using one-
way analysis of variance (ANOVA) with Tukey’s post hoc test.
Values of p ≤ 0.05 were considered significant.
RESULTS
Establishment of a Solid and
Reproducible Method for Keratinocyte
and Fibroblast Isolations From Routinely
Discarded Tissues of the
Cranio-/Orofacial Region
To advance and promote discovery and translational research
on CFAs we initiated a long-term project in establishing a
living cell repository of the cranio-/orofacial region. The initial
aim was to collect routinely discarded tissues made available
by the Pediatric Surgery Division, Children’s Hospital, Bern,
and the Dental School, University of Bern. While we put our
priority on the establishment of a highly robust and reproducible
process for the isolation of patient-derived cells, our strategy
also allowed us to collect and biobank corresponding tissues for
histological analyses and snap frozen tissues for RNA and DNA
extractions (Figure 1).
The core of our biobank is represented by a collection of
patient-derived cells of the cranio-/orofacial region. Our main
goal is to specifically collect epithelial cells (keratinocytes) and
the corresponding mesenchymal cells (fibroblasts) from the same
tissue donor by the explant culture approach (Figure 2A). The
opportunity to collect both cell types from the same individual
will allow the establishment of relevant 3D-co-culture systems
that closely mimic the in vivo situation, or the analysis of
the preferred individual cell type in line with specific research
interests in the future (see section “Our Cell Bank Offers Novel
Tools and Models for Personalized Precision Medicine”).
To successfully biobank all materials as described in our
strategy, the tissue biopsy we receive should ideally have a
minimal size of 0.1 cm3. With this specimen size we are able
to isolate keratinocytes and fibroblasts, prepare FFPE blocks,
FIGURE 1 | Schematic diagram summarizing the strategy of our CFA
biobank. The Pediatric Surgery Division, Children’s Hospital, Bern, and the
Dental School, University of Bern are responsible for tissue excisions and, if
required, for further diagnostic analyses of the biopsies (blue boxes). Usually,
tissues from the cranio-/orofacial region are discarded after their initial excision
(no diagnosis required) or after their diagnostic analysis (medical waste, red
box). The research laboratory (Laboratory for Oral Molecular Biology,
University of Bern) collects such specimens and processes them in order to
create a living cell repository of patient-derived cells (Cell Extraction). After
isolation of the cells, if the tissue size allows it, the remaining tissue remnants
are (1) stored in freezing medium in the liquid nitrogen tank for future
processing and new cell extractions (Tissue Storage), (2) formalin-fixed and
paraffin-embedded (FFPE) for histological analyses (Tissue Histology), and (3)
snap-frozen for future tissue RNA and/or DNA extractions (Snap-Frozen
Tissue). These patient-derived resources can be used for several downstream
applications in discovery and translational research projects. Our workflow is
highlighted in yellow.
snap-freeze the sample, and store some of the tissue biopsy in
liquid nitrogen for future use (Figure 1). When we receive tissues
<0.1 cm3, we prioritize our work and focus on cell isolations and
storage of the tissue in freezing medium in the liquid nitrogen.
Tissue samples are collected in sterile 50 ml tubes containing
25 ml of Collection Medium (CM). Within less than 1 h after
biopsy, tissue samples are processed (Figure 2A-2). For cell
isolations we apply the explant culture technique, which is
extensively described in section “Cell Isolation and Culture.” First
cells usually emerge within 4 days at 37◦C, and colonies are
ready for subculturing after approximately 10 days in culture
(Figure 2A-3a). Pure cells are expanded (Figure 2A-4), checked
for quality (Figure 2A-5, also see section “Cell Isolation and
Culture”) and finally frozen (usually 11 cryovials) for long-term
storage in liquid nitrogen (Figure 2A-6).
If required, tissue pieces with successful cell outgrowths can be
carefully transferred into a new well of a six-well plate containing
800 µl of CM allowing a 2nd round of explant cultures from
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FIGURE 2 | Establishment of a robust and reproducible method for the isolation of keratinocytes and fibroblasts. (A) Illustration of the process we follow for the
isolation of patient-derived cells from tissue biopsies. A representative example for a CLP biopsy is shown. Briefly, lip tissue from a corrective CLP surgery, which
would be routinely discarded (medical waste), is collected in Collection Medium (CM) and transferred to the laboratory (1). After mincing the tissue biopsy, two small
tissue fragments of about 0.1 mm3 are put in one well of a six-well culture plate containing 800 µl of CM (2). These six-well plates are then incubated at 37◦C/5%
CO2, re-fed every other day, and observed under the microscope for cellular outgrowths (3a). After approximately 10 days, outgrowths are usually ready for
(Continued)
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FIGURE 2 | Continued
subculturing (3a). Cells are trypsinized, expanded in their respective medium, quality checked, and finally frozen (at passage 2) in freezing medium and stored in a
liquid nitrogen tank (4–6). Note that in case of mixed keratinocyte/fibroblast cultures, differential trypsinization using 0.05% trypsin-EDTA (TE) solution for detaching
fibroblasts, followed by 0.25% TE to dissociate keratinocyte is applied (4). Also note that tissue pieces can be re-used for another round of cell isolation if required
(3b). Approximate incubation times (depends on cell type and tissue biopsies) are indicated in days. If a second round of cell isolation is required from an initial tissue
piece, the days are indicated in gray. Scale bar: 100 µm. (B) qPCR analyses of ten individual non-syndromic CLP cell cultures for the epithelial marker Keratin14
(KRT14) and the mesenchymal marker Fibronectin (FN). Although cells have been isolated from 10 different tissue donors, keratinocytes (orange) and fibroblasts
(green) express similar levels of KRT14 and FN, respectively among the cohort. n = 3 (biological replicates). (C) Analyses of CLP cells derived from three individual
donors (CLP021-CLP023) from two distinct cell isolations to show reproducibility of our cell isolation protocol. In between the first and the second cell isolation (light
vs. dark orange for keratinocytes, and light vs. dark green for fibroblasts), the tissue remnants have been stored in freezing medium in the liquid nitrogen tank for at
least 3 years. qPCR shows comparable expression of KRT14, Laminin α3 (LAMA3), and Transforming Growth Factor β1 (TGFβ1) in keratinocytes (orange), and of
FN, Tenascin-C (TNC) and TGFβ1 in fibroblasts (green) derived from two consecutive cell isolations (Isol. 1: Isolation 1; Isol. 2: Isolation 2). n = 3 (technical replicates).
the same tissue (Figure 2A-3b). This possibility is especially
useful when the initial biopsy is rather small. Note that each of
the fibroblast and keratinocyte primary cell cultures originating
from individual donors represent a mixture of fibroblasts and
keratinocytes that grew out of multiple explants.
In our experience, we do get successful cellular outgrowths
from approximately 75% of the small tissue pieces. Emergence
of the first cells is usually observed 3–4 days after initiation
of the explant cultures. Keratinocytes are often growing out
of the tissues faster than fibroblasts, which is beneficial as the
keratinocytes help to attach the tissue pieces to the culture dish.
In order to minimize the risk of inter-experimental
variations during cell isolation, which would hamper any
future comparative studies, we follow a highly reproducible
workflow. Here, our main rules for cell isolations are detailed.
First of all, tissues are all processed in the research laboratory
within 1 h after collection. In rare cases, if this is not possible,
tissues are stored at 4◦C for longer times, and this is properly
annotated in the digital databank platform. Secondly, only a
team of three well-trained laboratory scientists is in charge of
the practical performance of the explant cultures. Thirdly, a
strict adherence to Standard Operating Procedures (SOPs) is
maintained. SOPs rigorously define the outline of the practical
work as well the responsibilities along the cell isolation process,
starting from the tissue collection until the final inclusion of the
sample into the biobank database. To test whether following these
rules was enough to establish a highly robust and reproducible
cell isolation process, we tested ten cell strains that have been
isolated from ten different non-syndromic, age-matched CLP
lip tissue donors for the variability in mRNA levels of some
genes. We assumed that patient-derived keratinocytes as well
as fibroblasts from the same passage and cultured to the same
cell density should display similar levels of the genes Keratin14
(KRT14) and Fibronectin (FN), respectively. Figure 2B clearly
indicates that KRT14 and FN are very evenly expressed within the
group of tissue donors tested (CLP001-CLP010 p > 0.05). Our
biobank strategy also includes the storage of tissue remnants in
freezing medium in liquid nitrogen for potential cell re-isolation
(secondary isolation). Robustness and reproducibility of our cell
isolation protocol should result in identical cells after initial and
secondary isolation from the same tissue donor. Therefore, we
re-isolated cells from three individual tissue biopsies (CLP021-
CLP023) that have been stored in freezing medium in the liquid
nitrogen tank for more than 3 years (initial cell isolations:
2016–2017; secondary cell isolations: 2020–2021) according to
our established SOP (Figure 2A). Keratinocytes and fibroblasts
from secondary isolations were indistinguishable from the
initially isolated cells in regard to cell growth and morphology
(data not shown). Moreover, we used a qPCR approach to
determine gene levels of the two independent isolations. Cells
of the same passage (passage 3) and at the same density (60%)
were compared. In keratinocytes (orange), KRT14, Lamininα3
(LAMA3), and Transforming Growth Factor β1 (TGFβ1) levels
were indistinguishable in the original (light orange) and the
“secondary” cells (dark orange) isolated from the same tissue
donor (Figure 2C). Similarly, we did not detect any significant
differences in the levels of FN, Tenascin-C (TNC), and TGFβ1
in the fibroblasts from the primary (light green) vs. secondary
(dark green) cell isolations (Figure 2C). The robustness of
our explant assay guarantees that variations among individual
patient-derived cell strains in regard to gene expression are only
minimal as long as cell density, donor age, and anatomical site
are comparable. Therefore, whenever a significant difference in
gene or protein level is detected, this change might be real and
relevant for the condition studied. In summary, we show that
we have established a highly robust and reproducible explant
culture protocol for the isolation of patient-derived fibroblasts
and keratinocytes, which allows comparative studies as well.
Patient-Derived Cells Have to
Successfully Pass a Quality Control
Analysis Before Being Biobanked
Problems associated with the establishment of new cell strains,
such as misidentification or mycoplasma contamination, are
often ignored by the research community and may lead
to unreliable research data (Drexler and Uphoff, 2002).
Therefore, prior to biobanking, our newly isolated cells
are submitted to a standardized quality control procedure
(Figure 3).
Morphology and Gene Expression
To gain pure fibroblast and keratinocyte cultures, we have to
avoid possible contaminations with the counterpart cell type. The
morphologies of fibroblasts and keratinocytes allow the simple
monitoring of cross-contaminations by brightfield microscopy
and, if required, the two cell types are purified by the differential
trypsinization approach as described above. Pure keratinocyte
cell cultures suitable for biobanking should form regularly
shaped and cohesive colonies (Figure 3A, first column), while
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FIGURE 3 | Before biobanking, newly isolated cell cultures undergo a standardized quality control check. (A) In a representative set of primary cells (CLP-Lip,
Forehead, Gingiva, and PDL) live imaging pictures show typical cell morphologies of the patient-derived keratinocytes (orange) and fibroblasts (green). While
keratinocytes form tightly packed and cohesive colonies, fibroblasts appear with an elongated and spindle-like shape. Scale bar: 50 µm. (B) The same set of primary
cells was used for qPCR (top) and immunoblot analysis (bottom) confirming E-Cadherin (CDH1) and fibronectin (FN) expression in keratinocytes (orange bars) and
fibroblasts (green bars), respectively. Data are expressed as mean ± SD. n = 3. (C) Mycoplasma contamination of the new cell cultures is tested by DAPI staining of
the nuclei and a PCR-based mycoplasma detection analysis. DAPI staining and PCR amplifications are shown to confirm absence of mycoplasma contamination in
the same representative set of newly isolated primary cell cultures. Scale bars: 25 µm (Live Imaging keratinocytes), 50 µm (Live Imaging fibroblasts), 10 µm (DAPI).
+positive control; –negative control; PDL: periodontal ligament. *p < 0.05 Ep vs. Fb. (D) Lifespan analysis of two representative keratinocyte (CLP lip, red, and
forehead, orange) and two fibroblast strains (gingiva, green, and PDL, yellow) reveals that all cell cultures tested have a replicative potential of at least 35 population
doublings (PD). The age of the tissue donors is indicated in the brackets. Y: year; Ep: epithelial cells; Fb: fibroblasts.
fibroblast cultures should appear as homogenous monolayers
of flat, elongated and spindle-shaped cells (Figure 3A, second
column). However, cell purity and identity are not only assessed
by visual examinations of their morphologies, but also by
qPCR and immunoblots for epithelial and mesenchymal markers
(epithelial markers: E-Cadherin, Laminin γ2 and Keratin14;
mesenchymal markers: Fibronectin, Vimentin and Tenascin-C).
Figure 3B shows that the epithelial cells (Ep, orange bars) only
express E-Cadherin, but not Fibronectin, and vice versa for the
mesenchymal cells (Fb, green bars).
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Mycoplasma Contamination Detection
Although we strictly follow the rules of good laboratory practice,
there is always the risk of mycoplasma contamination when
working with primary cell cultures. The original source of tissue
serves as the most probable source of mycoplasma in primary
cell cultures, but contamination can also occur from exogenous
factors (Barile and Rottem, 1993; Rottem et al., 2012). Testing
for potential mycoplasma contaminations is a prerequisite for
setting up a living cell repository. We routinely test all our
newly isolated cell cultures for mycoplasma contamination by
a DAPI- and PCR-based detection approach (Praetorius, 2015).
Figure 3C shows examples of nuclei stained by DAPI without
any signs of mycoplasma contamination in combination with the
corresponding PCR-based mycoplasma detection test. A primary
cell culture that is found to be contaminated is discarded
so that only mycoplasma-negative cells are finally biobanked.
So far, only one cell strain derived from a CLP patient was
found to be mycoplasma-positive and hence excluded from
the biobank.
Lifespan Assessment
Primary cell cultures have a finite lifespan. In order to
promote them as promising cell models to study human CFAs,
the patient-derived cells must possess a replicative potential
allowing successful experimental manipulations. To assess this
requirement, we regularly perform lifespan analyses with our
newly isolated fibroblast and keratinocyte cultures. Figure 3D
indicates that our patient-derived cells can be consistently
propagated beyond 35 population doublings (PDs). This is
substantially shorter than what has been reported for infant
foreskin epidermal keratinocyte primary lines such as strain N,
but similar to the lifespan of other p63-positive human epithelial
cell types (Dabelsteen et al., 2009). It is evident that the replicative
lifespan depends on cell types, cell origin, and donor age, which
makes such comparisons difficult. Still, we are able to routinely
grow our cells for more than 80 days and keep them healthy
growing up to passage 11, which makes them highly suitable for
standard research activities.
CFA BIOBANK – State of Our Living Cell
Repository
Since April 2016, we received a total of 92 tissue biopsies from
the cranio-/orofacial region of 71 different donors (Table 1).
Samples can be grossly classified into four distinct groups in
respect to their origin: (1) skin-derived specimens (n = 12;
forehead, eyebrow, ear, nose and facial skin); (2) mucosa-
derived specimens (n = 14; palate, oral mucosa, “lip pits” and
gingiva); (3) mucocutaneous junction area-derived specimens
(n = 53; CLP lip, upper lip, lower lip and lip scar); (4)
tooth-derived specimens (n = 13; PDL and dental pulp)
(Figure 4A).
The majority of our biopsy collection (60/92–65%) is
represented by discarded tissue excised during corrective
surgeries of CFAs. In addition, we biobanked four pediatric
healthy facial skin specimens (4/92–4.3%) and 3 healthy lip
samples (3/92–3.3%) obtained during surgeries for minor
injuries (i.e., lip laceration, accidental cuts). The remaining
samples were collected as tissue remnants after routine dental
treatments (21/92–22.8%) performed at the Dental School,
University of Bern or after secondary surgeries at the Pediatric
TABLE 1 | Total status of our cell bank, including the tissue category, number of samples, cell types that have been successfully isolated, donor sex and age as well as
disease status (specifics).
Category # Samples Cells Donor Sex Donor Age Specifics
Ep Fb M F n.a. healthy diseased CFA
ns s
Skin Forehead 1 X X 1 0 0 2–4 years 1
Eyebrow 1 X 0 0 1 2–4 years 1
Ear 1 X X 0 0 1 n.a. 1
Nose 1 X X 1 0 0 2–4 years 1
Facial skin 8 X X 5 3 0 3–5 months 7 1× GH (F)
Mucocutaneous
junction area
CLP Lip 48 X X 30 18 0 3–5 months 46 1× VWS (M) 1× T13 (F)
Upper Lip 3 X X 1 1 1 3–5 years 3 0
Lower Lip 1 X X 1 0 0 19 years 1× VWS (M)
Scar (lip) 1 X 1 0 0 19 years 1× VWS (M)
Mucosa Palate 2 X 1 1 0 >18 years 2
Oral Mucosa 4 X X 2 2 0 3–5 months 4
“Lip Pits” 1 X X 1 0 0 19 years 1× VWS (M)
Gingiva 7 X X 4 2 1 >18 years 4 2 1× VWS (M)
Teeth Periodontal Ligament 10 X 5 3 2 >18 years 10
Dental Pulp 3 X 2 1 0 >18 years 3
Diseased gingiva samples were received from periodontitis-affected patients. Ep: epithelial cells; Fb: fibroblasts; M: male; F: female; n.a.: not available; ns: non-syndromic;
s: syndromic; CFA: craniofacial anomaly; GH: Goldenhar syndrome; VWS: Van der Woude syndrome; T13: Trisomy 13. Cells that have been used in this study, including
cell name, donor sex, donor age, and characteristics are indicated.
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FIGURE 4 | Overall description of our living cranio-/orofacial cell repository. (A) Graphical illustration indicating the anatomical origin of stored tissue biopsies
(including non-cranio-/orofacial-derived specimens). Light pink indicates skin-derived specimens; pink indicates mucocutaneous junction area-derived specimens;
red indicates mucosal-derived specimens; while light yellow indicates tooth-derived specimens. Furthermore, a green border depicts healthy tissue while a red
border represents tissue with anomalies. For the gingiva, we have both healthy and diseased tissues (green and red border). The number in the boxes in brackets
represents the amount of tissues available. (B) Bar chart reporting the source of the specimens that were obtained for the generation of the living cell biobank. Total
number of cranio-/orofacial region biopsies: 92 biopsies. (C) Bar chart of the outcome after tissue biopsy processing. The color code is shown in the legend. Total
number of biopsies: 92.
Surgery Division, Children’s Hospital, Bern (4/92–4.3%)
(Figure 4B).
From this cohort of tissue biopsies, we so far processed 70
biopsies (70/92–76%) and were able to isolate cells from 69
samples (success rate 99%). The only tissue we were not able to
obtain cellular outgrowths was a gingiva sample. We successfully
isolated and purified 49 pairs of matching keratinocytes and
fibroblasts (49/69–71%), while for 7 (7/69–10%) biopsies we
could extract either only keratinocytes (eyebrow) or only
fibroblasts (3 facial skin, 2 palate, and 1 oral mucosa biopsies).
For additional 13 (13/69–19%) specimens (PDL, dental pulp, “lip
pits” and scar) the tissue origin did not allow the isolation of
keratinocytes. We did not yet perform cell extractions from 22
biopsies. Notably, we have remaining tissues of successful cell
outgrowths for 48 samples (48/69–69%), which are stored in
freezing medium in the liquid nitrogen tank for potential cell
re-isolation in the future (Figure 4C).
Additionally, our biobank contains cells isolated from 10
more samples independent from the cranio-/orofacial region
(Supplementary Table 3). This cohort resulted in eight successful
matching keratinocyte/fibroblast pairs (seven foreskins, one
thumb derived from polydactyly), while for two biopsies we only
could get fibroblasts (synovia and ankle scar from a pigmented
villonodular synovitis). The complete state of our biobank (CFA
and other sources) is shown in Supplementary Figure 1.
Our Cell Bank Offers Novel Tools and
Models for Personalized Precision
Medicine
Establishing Cell Models for the Study of Rare
Human Conditions in vitro
In 5–7% of all CLP cases, orofacial clefting can be part of
rare syndromes that present with additional anomalies outside
of the region of clefting and that are usually caused by a
single gene mutation, chromosomal abnormalities or exposure
to teratogens during pregnancy (Mossey and Modell, 2012;
Leslie and Marazita, 2013). In fact, at least 275 syndromes have
been identified, which are associated with a clefting phenotype
(Leslie and Marazita, 2013). As such, primary cells isolated from
syndromic CLP-affected individuals are also very appealing for
the establishment of clinically relevant cell models for the study
of rare conditions, as exemplified below. Among our cohort, there
are cells isolated from four individual patients affected by rare
human diseases/syndromes, Van der Woude syndrome (VWS)
(two patients) (Van Der Woude, 1954), Patau syndrome (Trisomy
13) (Miryounesi et al., 2016) and GH (Bogusiak et al., 2017). Short
descriptions of the main features associated with these syndromes
are reported in Figure 5 (Overview).
Regarding VWS, we have tissues and the corresponding cells
from 2 affected patients: an infant (VWS1), who underwent
primary corrective cleft lip surgery (CLP lip biopsy) and a 19 year
old individual (VWS2), who had secondary surgery for functional
as well as esthetical reasons (biopsies of the gingiva, lower lip,
connective tissue of the lip pits, and the scar tissue from the
primary corrective surgery to close the upper lip) (Figure 5A,
Biopsies). While we were able to isolate both fibroblasts and
keratinocytes from the lip and the gingiva tissues, we only
managed to obtain fibroblasts from the scar and the “lip pits”
connective tissue. We analyzed all cells for their morphologies as
well as epithelial (E-Cadherin)- and mesenchymal-(FN)specific
markers (Figure 5A, patient-derived cells). In addition, we
prepared FFPE blocks and tissue sections from all four VWS2-
derived biopsies. H&E and Toluidine Blue staining allow a
preliminary descriptive appreciation of the tissue architecture,
which could be further investigated by immunohistochemistry
(IHC) (Figure 5A, Histology). By IHC staining of some sections,
we were able to highlight the epidermis of the lip by E-Cadherin
expression at adherent junctions between epithelial cells, scar
tissue by strong positivity for α-smooth muscle actin (αSMA) in
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FIGURE 5 | Patient-derived cells can serve as promising research tools for studying rare human diseases. Our cohort of tissue donors encompasses individuals
affected by (A) Van der Woude syndrome (VWS), (B) Patau syndrome, and (C) Goldenhar syndrome (GH). Overview: A brief description of the rare human diseases
is shown as well as the clinical appearance of the tissue donors. Arrowheads indicate typical phenotypes such as bilateral lip pits and orofacial clefts (VWS1, A), and
(Continued)
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FIGURE 5 | Continued
pathological skin tags in the GH-affected individual (C). Biopsies: High magnification images of the tissue biopsies taken for histological analysis are depicted. Note
that the biopsies shown for the VWS were all derived from a secondary surgery of a 19 years old individual (VWS2) and are indicated by numbers (1, 3, 4) in the
“Overview” (A). Patient-derived cells: Explant cultures allowed the isolation of patient-derived cells of the biopsies shown, which were thoroughly characterized by
morphological as well as immunofluorescent analyses. All keratinocytes (orange) show the typical colony-forming morphology (Live Imaging) and are all positive for
the epithelial marker E-Cadherin (E-Cad), while fibroblasts (green) present as elongated cells (Live Imaging) positive for the mesenchymal marker Fibronectin (FN).
Note that explant cultures from the scar and the “lip pits” of the VWS2 individual (A) only resulted in fibroblasts. Scale bars: 25 µm (Live Imaging keratinocytes),
50 µm (Live Imaging fibroblasts), 25 µm (IF). Histology: Representative Toluidine Blue and/or H&E stainings of the tissues, with some close-ups are shown. For the
VWS2-derived samples additional immunohistochemical analyses (IHC) were performed (A). The expression of E-Cad indicating the skin epithelium was revealed in
the lower lip sample. Similarly, the scar tissue revealed excessive staining for α-smooth muscle actin (α-SMA). Note also the abundant amount of striated muscles in
the biopsy derived from the VWS2 “lip pits” connective tissue [anti-myosin II (MYOII) immunoreactivity and H&E/Toluidine Blue staining]. In the H&E staining of the
Patau syndrome biopsy (B) the transition zone between skin and mucosa of the lip can be appreciated (Vermillion border). Finally, Safranin-O staining of the skin tag
biopsied from the GH patient identifies the presence of pathological cartilage formation (C). Scale bar: 0.1 mm. In vitro characteristics: (A) qPCR and immunoblot
analyses show that the levels of IRF6 in VWS1 and VWS2 keratinocytes are significantly decreased compared to the levels in 4 non-syndromic [wild-type for the
VWS-associated genes IRF6 (NM_006147.4), GRHL3 (NM_198173), and NME1 (NM_198175)] CLP and one healthy lip keratinocyte cell cultures. These results
strongly suggest that the VWS2 individual harbors an IRF6 variant [this has been confirmed for VWS1 by genetic analysis (Degen et al., 2020)] (left). Additionally,
fibroblasts isolated from the scar tissue of VWS2 showed higher expression of α-SMA and Collagen type III (COL3) mRNA levels compared to fibroblasts isolated
from the same donor but from different origins (gingiva, lower lip, and “lip pits,” right). Thus, the original characteristics are retained in the patient-derived cells. Data
are expressed as mean ± SD. n = 3. * = p < 0.05. (B) Presence of three chromosomes 13 in the patient affected by the Patau syndrome is shown by karyotype
analysis (red box).
the stroma, and to confirm presence of high amounts of striated
muscles in the “lip pit” tissue, which were already visible in the
H&E sections, by Myosin fast II (MYO2) (Figure 5A, Histology).
Cellular and molecular analyses of the patient-derived cells
clearly demonstrated proof-of-concept: the original hallmarks
of the syndrome are retained in the cells in vitro and
represent promising study tools. Using the isolated keratinocytes
(VWS1) we were able to confirm and thoroughly characterize
a novel IRF6 variant (c961_965delGTGTAinsC), which has
been initially sequence-identified by the Division of Human
Genetics, Children’s Hospital Bern (Degen et al., 2020). Here,
we show that in keratinocytes derived from the VWS2, both
IRF6 protein as well as mRNA levels are comparable to
VWS1, but robustly decreased when compared to non-syndromic
(pathogenic variants in the known VWS-associated genes IRF6,
GRHL3, and NME1 have been excluded by whole exome
sequencing) CLP- and healthy lip-derived keratinocytes. These
data fit to the assumed notion that VWS-causing IRF6 mutations
often result in haploinsufficiency of IRF6 (de Lima et al.,
2009; Degen et al., 2020). Therefore, without knowledge of the
underlying gene defect causing VWS in the second individual, we
can speculate that the affected individual harbors a pathogenic
IRF6 variant (Figure 5A, In vitro characteristics). In addition,
gene expression analyses of the four different fibroblast cultures
derived from the VWS2 individual allowed us to show that also
fibroblasts retain their in vivo characteristics in vitro. Indeed,
the scar-derived fibroblasts significantly present higher levels of
the scar markers (Ehrlich et al., 1994; Tsou et al., 2000; Shinde
et al., 2017) αSMA, Collagen I (Col1) (data not shown) and
Collagen III (Col3) compared to the fibroblasts derived from
other tissues (Figure 5A, In vitro characteristics), fitting to our
IHC observations.
Among our cohort of tissue donors, there is also an
individual affected by Trisomy 13 (Figure 5B), who underwent
corrective surgery of the condition-associated orofacial cleft lip.
Successful isolation of both keratinocytes and fibroblasts will
allow scientists to study specific aspects of Trisomy 13 using
clinically relevant cells (Figure 5B, Patient-derived cells). We
collected the corresponding tissue as FFPE blocks. The initial
H&E staining shows the complex anatomical structure of the
lip as it represents a transition zone between mucosal and skin
tissue (Figure 5B, Histology). In addition, we show presence of
three chromosomes 13 by karyotype analysis (Figure 5B, In vitro
characteristics).
Finally, we received a biopsy from a patient who presented
with preauricular skin tags (Figure 5C, Overview and Biopsies),
a typical feature of GH-affected individuals (Dole et al., 2017).
From the biopsy, we were able to isolate and characterize
patient-derived keratinocytes and fibroblasts (Figure 5C, Patient-
derived cells). Such cells could represent an unprecedent research
opportunity for scientists interested in this rare syndrome, since
so far only one zebrafish model has been successful (Lopez
et al., 2016). Next to the cells, we also biobanked FFPE blocks.
Notably, H&E, Toluidine Blue and cartilage-specific Safranin-O
staining confirmed the presence of pathological cartilage in these
GH-associated skin tags (Figure 5C, Histology).
Our proof-of-concept study clearly shows that the patient-
derived cells, often in combination with the corresponding
FFPE blocks, represent promising tools to study rare human
conditions and that the original cell/tissue characteristics are
retained in vitro.
Potential Applications of Primary Cells in Preclinical
and Translational Research
Finally, we would like to illustrate the translational potential
of our living CFA cell bank in regard to regenerative and
personalized medicine as well as to pharmaceutical, cosmetic, oral
health and dental material industry.
Three-dimensional (3D) personalized skin models
Our approach of isolating keratinocytes as well as fibroblasts from
the same tissue donor is very promising for the development
of personalized 3D organotypic skin models, which mimic the
in vivo skin as much as possible (Ravi et al., 2015). In Figure 6A
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FIGURE 6 | Potential outlook for the use of patient-derived cells from the cranio-/orofacial region. (A) CLP patient-derived keratinocytes (orange) and fibroblasts
(green) were isolated from CLP patients and characterized by staining for E-Cad (keratinocytes) and FN (fibroblasts). Scale bars: 50 µm (Live Imaging), 25 µm (IF).
These cells were used to obtain 3D skin differentiation models (top) that can be stained for H&E, the proliferation marker PCNA (red) and Loricrin (LOR, green). Note
that PCNA is only detectable in basal keratinocytes, whereas LOR is present in more superficial keratinocyte layers confirming the in vivo situation. Dotted line
indicates the membrane. Scale bars: 50 µm (Live Imaging), 25 µm (IF). Alternatively, the isolation of both keratinocytes and fibroblasts from the same tissue donor
allows the establishment of full-thickness 3D-skin models, in which CLP keratinocytes are plated on a dermis created by the corresponding fibroblasts that also can
be stained (H&E, bottom). *p < 0.05 EtOH vs. oral rinse or KSFM or DMEM. (B) Healthy gingival keratinocytes (orange) and fibroblasts (green) were used to
determine cytotoxicity of a commercially available oral rinse (OR) at different dilutions after a 2 min exposure by MTT assay. Metabolic active cells are plotted as
percentage of the initial cell population. (C) Cranio-/orofacial derived fibroblasts share similar characteristics with MSCs and may have a potential in personalized
regenerative therapeutic approaches. Like MSCs, fibroblasts have a spindle-like morphology and are plastic-adherent, as revealed by live imaging and vinculin
staining (green). Furthermore, qPCR analyses revealed that our patient-derived fibroblasts also express the typical MSC markers CD73, CD90, and CD105.
*p < 0.05 MSC vs. Fbs. Alizarin Red S (AR) staining indicates the potential of PDL fibroblasts to be differentiated into bone forming cells. Scale bar: 20 µm. Data are
expressed as mean ± SD. n = 3.
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we present preliminary data on the establishment of 3D-skin
differentiation models (keratinocytes only) as well as on full
thickness skin models (fibroblasts and keratinocytes) using non-
syndromic CLP patient-derived cells. H&E stainings of both
models indicate that both assays result in models that nicely
resemble the in vivo skin with multiple superficial keratinocyte
layers. Loricrin, a differentiation marker of the granular layer
of epithelial cells can be detected in superficial keratinocyte
layers (green), while PCNA (red) is only expressed in the basal
proliferating keratinocytes (Figure 6A). Both observations are
identical to the in vivo situation.
Modern dentistry and biomaterials
Our provision of cells isolated from most of the tissues
represented in the oral cavity could be highly beneficial for
dental material companies, in order to improve and advance the
development of their products. For instance, primary gingival
fibroblasts could represent an optimal model for studying the
adhesion of soft tissues to the dental implant abutment or
to dental composites for the treatment of submucosal lesion,
while PDL and dental pulp fibroblasts may represent models
for studying the efficacy of treatment for periodontal and dental
regeneration, respectively. In addition, also the oral health
industry (e.g., companies interested in the development of oral
rinses or toothpastes) may benefit from clinically relevant cells
available in our cell bank. Such cells could be used for testing the
cytotoxic effects of new compounds in newly developed products.
Using keratinocytes and fibroblasts isolated from healthy gingiva
donors, we established straight-forward MTT assays to analyze
the cytotoxic effects of commercially available oral rinses on
paired gingiva-derived fibroblasts and keratinocytes (Figure 6B).
Tissue engineering and regenerative medicine
Our cohort of primary fibroblasts also shows certain criteria that
have been attributed to MSCs: they are plastic-adherent and show
a spindle-like morphology and express variable amounts of the
MSC surface markers CD73, CD90, and CD105. Furthermore,
our preliminary in vitro differentiation experiments revealed
that similar to MSCs, PDL fibroblasts could be induced into
bone forming cells as assessed by staining for Ca2+ deposits
by Alizarin Red S (Figure 6C). These initial observations let us
speculate that our patient-derived cells may represent a viable and
easily accessible source of cells likely offering some regenerative
potential. Clearly, further experimental evidence is warranted.
However, we are encouraged to believe that the fibroblasts in
our cell bank could be beneficial for the tissue donors themselves
later in life if they might benefit from autologous, regenerative
therapeutic options.
DISCUSSION
Discovery biomedical research is the foundation for an ever-
increasing gain of knowledge concerning the biological processes
underlying physiological as well as pathological craniofacial
development. In the past years, significant progress has been
made by using various model organisms to study genes required
for proper face morphogenesis. More recently, this approach
has been complemented by the availability of novel, state-of-
the-art technologies allowing the identification of disease-causing
gene mutations or chromosomal aberrations driving various
anomalies. Thanks to these approaches, hundreds of genes and
variants have been found to be linked to specific CFAs. However,
scientific activities also envision to understand how certain gene
mutations affect the behavior of cells and to establish genotype-
phenotype correlations (Degen et al., 2020). Immortalized cell
lines usually are used in such studies. However, nowadays, the
scientific community is aware that often immortalized cells fail
to recapitulate the in vivo situation as they often markedly
differ in their phenotypes as well as genotypes from the original
tissues. In addition, there are several reports about contaminated
and misidentified cell lines (Masters, 2010; Lorsch et al., 2014),
producing irreproducible results, on which many scientific
discoveries and publications rely on. Therefore, there is urgent
need for the availability of clinically relevant cell models that
retain their original characteristics and that can be used as in vitro
tools to further solidify the understanding of how genes affect
cellular behavior in studying CFAs.
Our effort in establishing a cell biobank represents an
unprecedented tool for the scientific community, who is
interested in studying CFAs or periodontal/dental-related
investigations. Such a project is only possible in a collaborative
effort with the clinical counterparts, which provide all clinical
samples. The availability of optimal cell models that retain
their original characteristics (Figure 5) should help to advance
discovery research on CFAs (see section “Establishing Cell
Models for the Study of Rare Human Conditions in vitro”), but
also could be of great benefit for the tissue donors themselves,
who can rely on a personal repository of autologous cells at
any moment of their life (Figure 6). In this regard, it is worth
noting that in the literature cranio-/orofacial tissues have been
described as very rich sources of progenitor cells or MSCs,
with potential application for regenerative therapies (Sanz et al.,
2015; Ebrahimi and Botelho, 2017). The International Society for
Cellular Therapy (ISCT) defined a set of three minimal criteria
that a cell has to fulfill in order to be viewed as an MSC (Dominici
et al., 2006). However, the true identity of MSCs is still debatable
as there is increasing evidence in the literature annotating similar
characteristics to fibroblasts (Ichim et al., 2018; Soundararajan
and Kannan, 2018). In this study, we show that some of the main
characteristics defined for MSC are present also in our set of
patient-derived fibroblasts (Figure 6). Clearly, more basic and
functional studies are required to assess the clinical potential of
patient-derived fibroblasts as alternatives to MSCs. However, our
preliminary investigations let us believe that our cell bank might
be beneficial for the tissue donors themselves for personalized
regenerative therapies in their future.
To be successful and relevant for the economy and society,
biomedical research increasingly relies on the existence and
usage of data and samples stored in human biobanks (Hewitt,
2011; Coppola et al., 2019). Biobanks are organized collections
of human biological samples and associated patient data, which
are stored over lengthy periods allowing the availability of
resources for research efforts. However, the establishment and
the maintenance of human biobanks raises multiple ethical
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and juridical questions, which need to be addressed (Ashcroft
and Macpherson, 2019). The acquisition, storage, and use
of patient-derived specimens is indeed subject to stringent
ethical as well as legal regulations. The protection of the
privacy and identity of the research participants should be the
top priority in all biobanking efforts. Unfortunately, there is
not yet a harmonized legislative framework available within
European countries regulating biobanking activities (Kaye et al.,
2016). For the establishment of our CFA biobank, we included
measures according to the https://www.wma.net/policies-post/
wma-declaration-of-helsinki-ethical-principles-for-medical-
research-involving-human-subjects/ and to the Swiss Human
Act (HRA), which regulate the protection of the privacy and
identity of participants on a global level and in Switzerland,
respectively. First of all, all the projects involving the use of
our cell models have to be approved by the regional research
ethical committee. In addition to this, external investigators
interested in using our cells are required to undersign a Material
Transfer Agreement (MTA), a contract governing the transfer,
intended use and rights of the research material. Secondly, all
study participants or their legal representative in case of minors,
are informed about the research and gave an informed consent,
which allows individuals to decide whether and how their tissues
samples can be used for research purposes. In both cases, patients
have always the right to decide whether their personal data
and tissue samples can or cannot be used in an encoded way
for future biomedical research. Participants are also informed
about the possibility to withdraw their consent at any time,
which further exemplifies the protection and respect toward
each individual. Notably, all the samples stored in our collection,
are derived from planned and necessary surgical interventions,
and all the biospecimens would have been otherwise discarded.
Therefore, none of the participants experiences any supplemental
consultation time, harm or any other disadvantages by donating
their tissue for research purposes. Finally, we implemented
various technological data security measures including the
appropriate IT infrastructure in order to securely store patient
data in a protected database.
In our workflow, the improvement of the protection of the
patient’s privacy has been obtained by defining clear and strict
responsibilities shared between the Children’s Hospital/Dental
School and the research laboratory for the collection and
encoding of the samples. All the clinically related data and work,
such as the written consents, consultation and the diagnosis,
are securely stored at the hospital/dental clinic. The laboratory
receives the tissue sample in a pre-labeled tube (e.g., 001) in
combination with minimal patient information (such as date
of the surgery, age and gender) and the origin of the sample
(e.g., bilateral cleft, gingiva). If applicable, the laboratory is also
informed about the presence of any syndromes associated with
the patient. This system does not allow the identification and
tracking of patients and hence protects their privacy. If future
research projects require more information about the tissue
sample donor (e.g., patients requiring regenerative therapies
using their own cells), this can only be achieved in consultation
with the involved and trained personnel of the clinics. Clearly,
it is our responsibility to regularly train all people involved in the
biobanking process and to audit all our activities to ensure correct
adherence to our guidelines.
We strongly believe that our approach in setting up a living
cell repository for the cranio-/orofacial region derived from
otherwise discarded tissues is unique and will represent an
important asset for discovery and translational research on
cranio-/orofacial anomalies as well as an essential tool to be
combined with animal studies. 3D skin models established from
patient-derived cells can be used as personalized organotypic
cultures for drug screenings (e.g., to obtain better wound healing
using CLP cells), cosmetics (facial skin cells), toxicity tests (oral
cavity cells), bacterial infections related to periodontitis (gingiva
cells) as well as for clinically relevant discovery research trying
to elucidate specific molecular mechanisms. For instance, we
applied such models in the understanding of how specific gene
variants causing CLP and/or VWS affected the differentiation
potential of skin and mucosa cells (Degen et al., 2018, 2020).
Another research area that might benefit from such clinically
relevant primary cells is dentistry. For the long-term success
of regenerative procedures in dentistry, the integration of
biomaterials within the oral cavity is of great clinical importance
(van Steenberghe et al., 1991; Tayebi and Moharamzadeh, 2018).
This largely depends on the behavior of cells at their interface and,
particularly, on their initial attachment, adhesion and spreading
(Anselme, 2000). However, these events can also be affected by
the characteristics of the material itself, and this is the reason for
why the development of more and more performant materials
is currently a trend on the market. In spite of this, most of the
available materials used in the daily clinical practices lack in vitro
data, which could support and explain their clinical performance
on a cellular level regulating biological events at the biomaterial
interface (Parisi et al., 2020; Toffoli et al., 2020). Our primary
dental-related cells could fill this gap and provide an optimal
source for clinically relevant and tissue-specific cells. We are
well aware that such a biobanking effort is time-consuming and
requires a financial investment (e.g., infrastructure, IT support,
trained personnel). Nevertheless, we are convinced that such
a cell bank might be required in the pursuit of a complete
understanding of specific CFAs, from which patients may benefit
in the future.
In summary, here we presented our proof-of-concept study
that patient-derived cells from the cranio-/orofacial region have
great potential in discovery and translational research. We
detailed our workflow and the main processes that we apply
for the ongoing generation of our biobank to (1) promote,
boost, and advance biomedical research on CFAs with high-
quality primary cells, (2) have healthy primary control cells
available from various cranio-/orofacial tissues, (3) establish
patient-derived cell models for translational research such as
drug testing using clinically relevant cells, (4) store patient-
derived cells that could be used at a later time as an autologous
source for personalized regenerative applications, and (5) gain
more and urgently needed knowledge on the biological processes
underlying various CFAs, which will be of great benefit to
CFA-affected patients.
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